AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Standard BioTools to report Q2 2025 financial results on August 11.
ByAinvest
Monday, Jul 21, 2025 7:06 am ET1min read
• Standard BioTools reports Q2 2025 financial results on Aug 11, 2025. • Company will host conference call and webcast at 4:30 p.m. ET. • Dial-in for US domestic callers: 888-346-3970. • Dial-in for outside US callers: 412-902-4297. • Live audio available on company's website. • Webcast will be archived on the Investor Relations page.
Standard BioTools Inc. (NASDAQ: LAB) has scheduled its second quarter 2025 earnings conference call for Monday, August 11, 2025, following the market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss its financial results and operational progress for the quarter.Investors can participate in the conference call by dialing:
- US domestic callers: (888) 346-3970
- Outside US callers: (412) 902-4297
The live audio of the webcast will be available online on the Investor Relations page of the company's website. The webcast will also be archived and accessible on the Investor Relations page at investors.standardbio.com.
Standard BioTools Inc., a leading provider of next-generation technologies, focuses on helping biomedical researchers develop better medicines faster. The company's proprietary technologies, including SomaScan, mass cytometry, and microfluidics, enable reliable and repeatable insights in health and disease, transforming scientific discoveries into improved patient outcomes.
For more information, visit Standard BioTools' Investor Relations page at investors.standardbio.com or connect with them on social media platforms like X, Facebook®, LinkedIn, and YouTube™.
References:
[1] https://www.stocktitan.net/news/LAB/standard-bio-tools-schedules-second-quarter-earnings-conference-call-mr4qp52zdn2w.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet